DALLAS — An electronic patient rehabilitation application used alone or with home health services led to improved patient reported outcomes 12 weeks after total hip arthroplasty and may mitigate the need for home health services in these patients, according to results presented at the American Association of Hip and Knee Surgeons Annual Meeting.
Roy I. Davidovtich
, MD, and colleagues randomly assigned 454 patients who underwent THA between November 2016 and August 2017 to use an electronic patient rehabilitation application (EPRA) either alone or in conjunction with home health services (HHS). They collected baseline demographics, EPRA-engagement and patient-reported outcomes at 12-week follow-up for the patients whose average age and American Society of Anesthesiologists scores were 64 years and 2.24 in the EPRA-HHS group and 59 years and 1.63 in the EPRA-only group.
“EPRA is noninferior to EPRA with home health in providing postop[erative] care in select patients populations. This is really important, especially in our current day and age,” Davidovitch said.
Results showed greater changes in patient reported outcome scores in the EPRA-only group at 12-weeks and the SF-12 mental and physical scores improved as did the Hip Disability and Osteoarthritis Outcome Score (HOOS) Jr., he noted.
“What we also saw was that the HOOS Jr. improvements had the greatest effect where outliers were reduced in the EPRA-only group,” Davidovitch said.
Patients in the EPRA-only group had a greater increase in EPRA engagement at the 12-week follow-up than the EPRA-HHS group, he added.
A cost analysis showed an average savings of $5,000 per episode of care based on costs in the New York City area where the study was conducted, according to Davidovitch.
“This equated to approximately $150,000 during the study’s short duration,” he said. – by Casey Tingle
Davidovitch RI, et al. Paper #12. Presented at: American Association of Hip and Knee Surgeons Annual Meeting; Nov. 2-5, 2017; Dallas.
Disclosure: Davidovitch reports he is a paid consultant for Medtronic and Radlink; and receives IP royalties and stock or stock options from Radlink.